Carmat SAS, the French government-backed developer of a total artificial heart (TAH) for end-stage biventricular heart failure, has CE marked its device and plans to roll it out commercially in the first quarter of 2021, starting in Germany and Kazakhstan.
CE marking was granted on 22 December for the Carmat TAH system as a bridge to transplant in patients suffering from end-stage biventricular heart failure (Interagency Registry for Mechanically Assisted...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?